Moath Hattab

Dr. Moath Hattab


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Radiology Case Reports
Verified
Journal Article
Open access
ZSZaid Sawaftah
Zaid Sawaftah
KSKhaled Sawafta
Khaled Sawafta
MHMoath Hattab
Moath Hattab
ARAdel Abu Al Rub
Adel Abu Al Rub
OSOmar Sawafta
Omar Sawafta
YDYazan Dibas
Yazan Dibas
Zinner syndrome (ZS) is a rare congenital urological condition characterized by a triad of ipsilateral seminal vesicle cysts, unilateral renal agenesis, and ejaculatory duct obstruction, first described in 1914. This case report details the presentation and management of a 27-year-old male diagnosed with ZS following a 2-month history of urinary frequency, hesitancy, dysuria, and painful ejaculation. Physical examination revealed a left lower abdominal mass, and imaging confirmed the classic findings of ZS, including unilateral renal agenesis, an enlarged seminal vesicle cyst, and an ectopic ureter. Conservative treatment with tamsulosin initially improved symptoms, but due to the cyst's large size and the risk of complications, laparoscopic excision was recommended for definitive management. ZS is often diagnosed late due to nonspecific symptoms, with an average diagnosis age of 29.35 years. MRI is the gold standard for diagnosis, revealing seminal vesicle cysts, renal agenesis, and ejaculatory duct obstruction. Conservative management is reserved for asymptomatic cases, while symptomatic patients benefit from surgical intervention. This case emphasizes the importance of timely imaging, particularly in patients with nonspecific lower urinary tract symptoms, and highlights the role of tamsulosin as an effective interim therapy before definitive surgical treatment. The case underscores the need for clear diagnostic criteria and treatment pathways to improve outcomes in this rare condition, which can lead to infertility if not managed appropriately.

24 April 2026 in Scientific Reports
Verified
Journal Article
Open access
LSLana Saed
Lana Saed
MBManal Badrasawi
Manal Badrasawi
MBMira Braik
Mira Braik
ADAmneh Dibas
Amneh Dibas
MMMasa Maqboul
Masa Maqboul
MHMoath Hattab
Moath Hattab
Celiac disease (CD) is an autoimmune disease. Since the only treatment is a lifelong strict gluten-free diet (GFD), good adherence is the cornerstone. No research has examined the degree of GFD adherence among CD patients in Palestine and how it impacts the disease activity and prognosis. Therefore, this study aims to determine the level of adherence to GFD among adult patients with (CD) in Palestine, and its association with disease activity, mental health, patients’ awareness, attitude, barriers, lifestyle, and sociodemographic variables. The study involved 137 patients with celiac disease using a cross-sectional design. Participants were recruited from private and governmental clinics, as well as community-based lists and associations. Disease activity was measured using the Celiac Symptom Index (CSI), mental health was measured using the General Health Questionnaire (GHQ-12), and knowledge, awareness, attitudes, and barriers were assessed using a structured questionnaire developed by the research team. Adherence level was measured through the participants’ practices section of the questionnaire. A multivariate logistic regression was performed. The mean age of participants was 37.7 ± 13.1 years, and the majority were female (71%). Overall, 36.5% of participants demonstrated high adherence, 61.3% moderate adherence, and 2.2% low adherence. Bivariate analysis showed that symptom burden (CSI), psychosocial distress (GHQ-12), subjective knowledge, attitudes, and barriers related to meal preparation and social situations were significantly associated with adherence ( P < 0.05). However, multivariate analysis identified a more positive attitude toward a gluten-free diet as the most consistent independent predictor of higher adherence, while the association with male sex was weaker and less stable across sensitivity analyses. A more positive attitude toward a gluten-free diet was the most consistent independent correlate of higher adherence, while the association with male sex was weaker and less stable across sensitivity analyses. These findings underscore the central role of attitudinal factors in shaping adherence and support the development of targeted, culturally sensitive interventions to optimize outcomes in patients with celiac disease.

28 October 2025 in Research Square
Verified
Preprint
Open access
PDF file
MHMoath Hattab
Moath Hattab
FMFathi Milhem
Fathi Milhem
HJHammam Jallad
Hammam Jallad
MSMahmoud Suleiman
Mahmoud Suleiman
HAHalla Albada
Halla Albada
Mohammad BdairMohammad Bdair
Mohammad Bdair
Background Helicobacter pylori (H. pylori) has been implicated in immune thrombocytopenia (ITP), but the magnitude and reliability of benefit from eradication therapy in randomized trials remain uncertain. Methods We performed a PRISMA-guided, PROSPERO-registered (CRD420251149478) systematic review and meta-analysis restricted to randomized controlled trials (RCTs) comparing H. pylori eradication versus control in ITP. Random-effects models (R) generated risk ratios (RRs) for categorical outcomes—complete response (CR; 8 trials), partial response (PR; 5), overall response (CR + PR; 8), no/minimal response (NR; 8), and 1-year relapse (3)—and mean difference (MD) for platelet count change at ~ 6 months (5). Heterogeneity (I²/τ²), leave-one-out sensitivity, and funnel plots with Egger/Begg tests assessed robustness and small-study effects. Results Eight RCTs (n = 297) across Asia and Latin America met inclusion. Eradication increased CR without statistical significance (RR 1.45, 95% CI 0.87–2.41; I²=40.9%) and did not change PR (RR 0.88, 0.57–1.36; I²=0%) or overall response (RR 1.04, 0.90–1.20; I²=35.9%). NR was significantly lower with eradication (RR 0.65, 0.49–0.85; I²=14.8%). Relapse at 1 year trended lower but was not significant (RR 0.49, 0.24–1.01; I²=0%). Platelet counts rose more after eradication at ~ 6 months (MD + 61.9×10⁹/L, 36.1–87.7; I²=74.9%). Leave-one-out analyses did not alter conclusions. Funnel plots and tests suggested asymmetry for CR and overall response; PR and NR showed no evidence of small-study effects; relapse and platelet change were underpowered for definitive bias testing. Adverse events were mild and infrequently reported; no serious events were attributed to eradication. Conclusions In RCTs, H. pylori eradication for ITP significantly reduces non-response and yields a clinically meaningful platelet rise, while effects on categorical CR/PR and overall response are neutral and relapse reduction is borderline. Given its safety, low cost, and biologic plausibility, testing and offering eradication should be considered early—especially in high-prevalence regions—pending larger multicenter trials to define predictors and durability of benefit.

1 January 2025 in Case Reports in Hematology
Verified
Journal Article
Open access
MTMuhammad Takhman
Muhammad Takhman
MHMoath Hattab
Moath Hattab
RSReem Shihab
Reem Shihab
ASAsmaa Sarama
Asmaa Sarama
SMSultan Mosleh
Sultan Mosleh
Gray platelet syndrome (GPS) is a rare inherited platelet disorder characterized by the presence of gray platelets on blood smears, resulting from a deficiency of α ‐granules. The thrombocytopenia presents in a spectrum of bleeding tendencies, varying among different patients. We present a case of a 14‐year‐old male presenting with recurrent epistaxis, thrombocytopenia, hepatosplenomegaly, and recurrent infections that had not been diagnosed previously. Whole‐exome gene sequencing revealed a homozygous likely pathogenic splice‐site variant in the NBEAL2 gene, confirming the diagnosis of GPS, which is inherited in an autosomal recessive manner due to biallelic variants in NBEAL2. The patient had atypical hepatomegaly and low lymphocyte and monocyte counts, findings consistent with emerging evidence that GPS affects multiple hematopoietic lineages. It also contributes to immune dysregulation and results in increased susceptibility to autoimmune disorders, highlighting the need for guidelines to screen for autoimmune complications in GPS patients.

28 May 2025 in Oxford Medical Case Reports
Verified
Journal Article
Open access
ARAbraam Rezkalla
Abraam Rezkalla
IRIslam Rajab
Islam Rajab
FMFathi Milhem
Fathi Milhem
MHMoath Hattab
Moath Hattab
YSYezin Shamoon
Yezin Shamoon
FSFayez Shamoon
Fayez Shamoon
Brugada Syndrome is a potentially fatal, hereditary cardiac disorder that may precipitate sudden cardiac death if not identified. An electrocardiogram (ECG) revealing a characteristic coved ST segment elevation followed by negative T wave in a right-sided precordial lead is pathognomonic for the Brugada pattern. Recently it has been shown that certain abnormalities, such as an electrolyte disturbance, may precipitate a Brugada pattern on ECG. Once the precipitating factor is treated, the rhythm reverts to baseline, coining the term Brugada Phenocopy. Here we present a captivating case of a 40-year-old female who was found unresponsive and determined to have a Brugada pattern on ECG secondary to hyperkalemia. Once appropriately treated, ECG reverts to normal baseline.

14 April 2026 in Research Square
Verified
Preprint
Open access
FAFadi Abualhommos
Fadi Abualhommos
MHMoath Hattab
Moath Hattab
MSMasara Samara
Masara Samara
MSMahmoud Suleiman
Mahmoud Suleiman
ESEnas Samara
Enas Samara
ISIsra Salman
Isra Salman
Introduction: Ohtahara syndrome (OS) features neonatal-onset tonic spasms with suppression–burst EEG, high early mortality, and evolution to other epileptic encephalopathies. Respiratory complications are frequent yet under-described longitudinally. Case: We followed a female with neonatal-onset OS and suppression–burst EEG to age seven. Despite combination antiseizure therapy (phenobarbital, levetiracetam, vigabatrin, clonazepam), she had breakthrough events and severe developmental impairment. From ages 1–7 years, she experienced ≥15 documented hospitalizations for recurrent pneumonia/bronchopneumonia, frequently with hypoxemia requiring supplemental oxygen; several episodes were accompanied by seizure exacerbations and clinical aspiration/choking events. Management and outcomes: Admissions were managed with supportive respiratory care (oxygen, bronchodilators, corticosteroids when indicated) and broad-spectrum antimicrobials alongside ongoing seizure management, enabling survival to school age in a resource-limited context. Conclusions: In OS, respiratory disease, often driven by aspiration risk and impaired airway clearance, can become a dominant source of morbidity and should be addressed with the same priority as antiseizure therapy. We highlight practical pillars for long-term care: proactive infection prevention and early treatment pathways; aspiration-risk assessment with feeding/swallow support when feasible; airway-clearance planning with bronchodilator trials during illnesses; judicious corticosteroid use; and caregiver education with explicit thresholds for escalation.